Today: 18 November 2025
Subscribe
Browse Category

Mergers & Acquisitions News 4 November 2025 - 6 November 2025

Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

FRISCO, Texas — Nov. 6, 2025. Shares of Comstock Resources, Inc. (NYSE: CRK) traded higher today after a week packed with catalysts: stronger third‑quarter results, progress on a $430 million asset sale, and a fresh technical tailwind as the stock’s Relative Strength (RS) rating ticked up. Midday, CRK changed hands around $21.14, up roughly 5.5%, within a 52‑week range of $11.41–$31.17. Reuters What’s moving CRK today Technical momentum: Investor’s Business Daily highlighted CRK’s RS Rating rising to 85, a level technicians often view as signaling mounting relative strength. While IBD notes CRK isn’t at a formal “buy” point, the upgrade
6 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Key takeaways What happened today (Nov. 6) 1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1 2) Pfizer signals a sweeter counter—because the clock is tight.Reporting overnight indicates Pfizer plans to sweeten
6 November 2025
 ·  ·  ·  ·  ·  · 
SNAP Stock Just Got a 48‑Hour Jolt: India Creator Boom, New Sticker Push—and a $14B TikTok Twist Investors Can’t Ignore

Snap (SNAP) earnings today — Nov. 5, 2025: Revenue up 10% to $1.51B; $400M Perplexity AI deal and $500M buyback lift sentiment

Published: November 5, 2025 At a glance (Q3 2025) What happened today Snap reported September‑quarter (Q3 2025) revenue of $1.507B, up 10% year over year, with net loss narrowing to $104M (–$0.06 per diluted share). Management also authorized a $500M repurchase program, funded from Snap’s $3.0B cash and marketable securities balance. Snap Inc. Investor Relations User engagement continued to expand: DAUs reached 477M (+8% YoY) and MAUs climbed to 943M (+7%). Global ARPU improved to $3.16, with North America at $9.20, Europe at $2.99, and Rest of World at $1.11. Business Wire Why the stock is reacting After the bell,
5 November 2025
 ·  ·  ·  ·  · 
Alphabet (Google) GOOGL stock: What to Know Before Markets Open on October 20, 2025

Google (GOOGL) Stock Today: Alphabet Rises on Apple–Siri AI Tie‑Up, Epic Play Store Settlement, and DOJ Nod for $32B Wiz Deal — Nov. 5, 2025

Updated Nov. 5, 2025 (19:51 UTC). This article rounds up the major, same‑day developments affecting Alphabet/Google stock. At a glance: Alphabet (NASDAQ: GOOGL) traded roughly 2% higher intraday as three catalysts landed on the same day: reports that Apple will use Google’s Gemini AI model to power a revamped Siri, a proposed settlement with Epic Games that reshapes Android app‑store rules, and word that Google’s $32 billion acquisition of cloud‑security firm Wiz cleared U.S. DOJ antitrust review. Reuters+3Reuters+3Reuters+3 1) Apple reportedly picking Google’s Gemini to power a new Siri Bloomberg reporting (summarized by Reuters) says Apple plans to use a
5 November 2025
 ·  ·  ·  ·  ·  · 
Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Cheer Holding (CHR) Stock Skyrockets on Buyout Bids – Inside the AI Innovator’s Rollercoaster Ride

Company Overview: A Niche Chinese Digital Ecosystem Cheer Holding, Inc. is a China-based provider of advanced mobile internet infrastructure and digital content platforms. Through its subsidiaries, Cheer offers advertising and content production services in the Chinese market. The company has built a suite of consumer apps and services under the “CHEERS” brand, aiming to create an integrated digital ecosystem. Its flagship offerings include CHEERS Video (a short-video and live streaming app), CHEERS e-Mall (an e-commerce platform blending livestream shopping and online games), and CHEERS App which combines professionally-produced content with shopping features. In recent years, Cheer Holding has pivoted heavily
5 November 2025
 ·  ·  ·  · 
Dow Dips as Fed Fears Slam Tech Stocks – Hot Economic Data Rattles Wall Street (Sept 25, 2025)

Regional Banks Roar Back? Q3 Surprises, Mega‑Mergers—and the One Risk Still Haunting 2025

Key facts (updated Nov. 5, 2025): Q3 in one chartless glance: earnings stabilized, but credit is still a coin flip After two straight Fed cuts took the policy range down again in late October, the October Senior Loan Officer Opinion Survey painted a nuanced picture: tighter C&I standards on balance, but basically unchanged CRE standards and stronger demand for mortgages and HELOCs. In other words, lending isn’t shutting down, but banks are still protective—especially on business credit. Federal Reserve On the scoreboard, a sweeping Yahoo Finance/StockStory Q3 roll‑up of 94 regional lenders found revenues missed by ~1.2% versus consensus—yet the
5 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone reuters.com reuters.com. The share price is now hovering in the low $70s reuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emerged prnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4 reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Axcelis (ACLS) Stock Jumps on Q3 Earnings Beat and Veeco Merger: Key Insights & Outlook

Stock Price and Performance History Axcelis stock traded in the mid-$80s in early November 2025, rallying on earnings news. It closed around $86.24 on Nov 4, 2025, up about 5% for the day and roughly 8–9% over the two sessions surrounding its earnings report. This rebound comes after a soft October where ACLS had slid ~14% over a month nasdaq.com, underperforming the tech sector. Even after the post-earnings pop, shares remain well below their 52-week high of ~$103 and about double the 52-week low near $40 marketbeat.com, reflecting both the stock’s volatility and longer-term growth. Overall, year-to-date 2025 returns are
4 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share reuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performance reuters.com reuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal” reuters.com. This was weeks
4 November 2025
 ·  ·  ·  ·  ·  · 
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Company Overview & History Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” (knowledge) and “vue” (view), reflecting a vision of insight-driven care en.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter (OTC) medicines to skincare and baby care. Today its portfolio spans three segments investing.com: Formally incorporated in 2022, Kenvue began trading on the NYSE (ticker KVUE) in May 2023 after a highly anticipated IPO en.wikipedia.org. The IPO raised $3.8 billion – the largest U.S. listing in nearly two years – and
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Stock Price and Recent Performance Year-to-date chart of Evoke Pharma (EVOK) stock through early November 2025. Shares were volatile throughout 2025, and the Q4 acquisition announcement (right end of chart) triggered a dramatic spike to new highs, bringing the stock roughly back to breakeven for the year tipranks.com. Evoke Pharma’s stock has experienced extreme volatility in recent weeks. After trading in the mid-$4 to $5 range through October, EVOK plunged 10.9% on November 3, 2025 to $4.59 at the close tipranks.com. The very next day, news of the buyout sent the stock exploding upward – EVOK opened around $10.70 on
4 November 2025
 ·  ·  ·  ·  · 
Denny’s Stock Soars on Buyout Bombshell – $620 M Deal, Q3 Misses & What’s Next

Denny’s Stock Soars on Buyout Bombshell – $620 M Deal, Q3 Misses & What’s Next

Stock Price & Recent Performance Denny’s stock was under pressure for most of 2025 before the buyout news. The share price started the year in the mid-single digits and drifted lower amid uninspiring financial results and sector-wide challenges. In fact, DENN hit a 52-week low of $2.85 earlier in the year marketbeat.com, reflecting investors’ pessimism about growth prospects. By late October, the stock was trading around the $4 mark, not far from where it stood five years ago, and well off the 52-week high of $7.73 marketbeat.com reached in late 2024. In the week heading into earnings, DENN even dipped
4 November 2025
 ·  ·  ·  · 
1 … 3 4 5 6 7 … 12
Go toTop